rev:  November 7, 2004


Return (human cytokine index)

Human Cytokine/Growth Factor/Chemokines Sample Spec sheets (subject to change without notice):

DATA SHEET:  recombinant Human MART-1 (MELAN-A) Protein

                                 Certificate of Analysis and Data Sheet

cat# RDI-PRO299       $562.00/5ug

        RDI-PRO299X   $875.00/10ug

Source: E.Coli

Background: MART-1 (also known as Melan-A) is a melanocyte differentiation antigen. It is present in melanocytes of normal skin and retina, nevi and in more than 85% of melanomas. This antibody is very useful in establishing the diagnosis of metastatic melanomas and has also been shown to be positive in adrenal cortical cells and tumors derived from them making it very helpful in distinguishing adrenal cortical neoplasms from other tumors which are negative for this marker.

Description : MART-1 or Melan-A is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Seven other melanoma associated antigens recognized by autologous cytotoxic T cells include MAGE-1, Tyrosinase, gp100, gp75, BAGE-1, and GAGE-1. Subcellular fractionation shows that MART-1 is present in melanosomes and endoplasmic reticulum. Human MART-1 is purified by proprietary chromatographic techniques.

Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation: Recombinant Human Mart-1 protein at 100µg/ml in 50mM Tris-Acetate, pH7.5, 1mM EDTA, 20% Glycerol without BSA and Sodium Azide.

Solubility: It is recommended to reconstitute the lyophilized Recombinant MART-1 in sterile 18MO-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

Stability: Lyophilized Human MART-1 although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution Human MART-1 should be stored at 4 C between 2-7 days and for future use below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Purity: Greater than 90.0% as determined by:

(a) Analysis by RP-HPLC.

(b) Analysis by reducing and non-reducing SDS-PAGE coomassie blue gel.

Dimers and aggregates: Less than 1% as determined by coomassie blue SDS-PAGE gel analysis.

Endotoxin: Less than 0.1 ng/µg (IEU/µg) of Human MART-1.

Usage: This material is offered for in vitro research use only-not for use in or onhumans or animals.

General References:

1. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Enk CD, Lotem M, Hochberg M, Melanoma Res 2004 Oct;14(5):361-5

2. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. Liao YP, Wang CC, Economou JS, McBride WH, J Immunol 2004 Aug 15;173(4):2462-9

3. Cross-presentation of human melanoma peptide antigen MART-1 to CTLs from in vitro reconstituted gp96/MART-1 complexes. Staib F, Distler M, Schmitt U, Cancer Immun 2004 Apr 16;4:3

4. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Zubovits J, Buzney E, Duncan LM, Hum Pathol 2004 Feb;35(2):217-23

5. HMB-45 (gp103) and MART-1 expression within giant cells in an atypical fibroxanthoma: a case report. Smith-Zagone MJ, Prieto VG, Timperman WW Jr, J Cutan Pathol 2004 Mar;31(3):284-6

6. Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression. Terheyden P, Schrama D, Andersen MH, Scand J Immunol 2003 Nov;58(5):566-71

Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.


Return (human cytokine index)

RDI Divison of Fitzgerald Industries Intl

34 Junction Square Drive

Concord MA 01742-3049


phone (978) 371-6446 or (800) 370-2222

fax     (978) 371-2266

Ordering terms

all rights reserved by any/all copyright holders?